Giant Shapiro steps for two-dimensional Josephson-junction arrays with time-dependent Ginzburg-Landau dynamics

Two-dimensional Josephson junction arrays at zero temperature are investigated numerically within the resistively shunted junction (RSJ) model and the time-dependent Ginzburg-Landau (TDGL) model with global conservation of current implemented through the fluctuating twist boundary condition (FTBC). Fractional giant Shapiro steps are found for {\em both} the RSJ and TDGL cases. This implies that the local current conservation, on which the RSJ model is based, can be relaxed to the TDGL dynamics with only global current conservation, without changing the sequence of Shapiro steps. However, when the maximum widths of the steps are compared for the two models some qualitative differences are found at higher frequencies. The critical current is also calculated and comparisons with earlier results are made. It is found that the FTBC is a more adequate boundary condition than the conventional uniform current injection method because it minimizes the influence of the boundary.Comment: 6 pages including 4 figures in two columns, final versio

The immunologically active site of prothymosin α is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients

Prothymosin α (proTα) is a 109 amino acid long polypeptide presenting distinct immunoenhancing activity in vitro and in vivo. Recent reports suggest that in apoptotic cells, proTα is cleaved by caspases at its carboxy(C)-terminus generating potentially bioactive fragments. In this study, we identified the peptide segment of proTα presenting maximum immunomodulatory activity. Calf thymus proTα was trypsinised, and the five fragments produced (spanning residues 1-14, 21-30, 31-87, 89-102 and 103-109) were tested for their ability to stimulate healthy donor- and cancer patient-derived peripheral blood mononuclear cell (PBMC) proliferation in autologous mixed lymphocyte reaction (AMLR), natural killer and lymphokine-activated killer cell activity, intracellular production of perforin, upregulation of adhesion molecules and CD25 expression. ProTα(89-102) and proTα(103-109) significantly fortified healthy donor-lymphocytes' immune responses to levels comparable to those induced by intact proTα. These effects were more pronounced in cancer patients, where peptides proTα(89-102) and proTα(103-109) partly, however significantly, restored the depressed AMLR and cytolytic ability of PBMC, by simulating the biological activity exerted by intact proTα. ProTα(1-14), proTα(21-30) and proTα(31-87) marginally upregulated lymphocyte activation. This is the first report showing that proTα's immunomodulating activity can be substituted by its C-terminal peptide(s). Whether generation and externalization of such immunoactive proTα fragments occurs in vivo, needs further investigation. However, if these peptides can trigger immune responses, they may eventually be used therapeutically to improve some PBMC functions of cancer patients. © Springer-Verlag 2006